As a complex disease with the complexity of molecular based-physiological alterations, cancer challenges scientist to develop a new anti-cancer drug with specific mechanism.1 Previously, we reported a new curcumin analogue, namely PGV-1 (Figure 1) to have potential anti-cancer activities against several cancer cells.2,3 Our studies showed that curcumin and pentagamavunon-1 (PGV-1) inhibit the activity of nuclear factor kappa B (NFκB) in vitro and interact with the HER2 receptor in silico. The gene discussed is NFKB1; the disease is cancer.